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Purpose: Retrospective analysis of 3D clinical treatment plans to investigate qualitative, possible, clinical
consequences of the use of PBC versus AAA.
Methods: The 3D dose distributions of 80 treatment plans at four different tumour sites, produced using PBC
algorithm, were recalculated using AAA and the same number of monitor units provided by PBC and clinically
delivered to each patient; the consequences of the difference on the dose-effect relations for normal tissue injury
were studied by comparing different NTCP model/parameters extracted from a review of published studies. In this
study the AAA dose calculation is considered as benchmark data. The paired Student t-test was used for statistical
comparison of all results obtained from the use of the two algorithms.
Results: In the prostate plans, the AAA predicted lower NTCP value (NTCPAAA) for the risk of late rectal bleeding for
each of the seven combinations of NTCP parameters, the maximum mean decrease was 2.2%. In the head-and-neck
treatments, each combination of parameters used for the risk of xerostemia from irradiation of the parotid glands
involved lower NTCPAAA, that varied from 12.8% (sd=3.0%) to 57.5% (sd=4.0%), while when the PBC algorithm was
used the NTCPPBC’s ranging was from 15.2% (sd=2.7%) to 63.8% (sd=3.8%), according the combination of
parameters used; the differences were statistically significant. Also NTCPAAA regarding the risk of radiation
pneumonitis in the lung treatments was found to be lower than NTCPPBC for each of the eight sets of NTCP
parameters; the maximum mean decrease was 4.5%. A mean increase of 4.3% was found when the NTCPAAA was
calculated by the parameters evaluated from dose distribution calculated by a convolution-superposition (CS)
algorithm. A markedly different pattern was observed for the risk relating to the development of pneumonitis
following breast treatments: the AAA predicted higher NTCP value. The mean NTCPAAA varied from 0.2%
(sd = 0.1%) to 2.1% (sd = 0.3%), while the mean NTCPPBC varied from 0.1% (sd = 0.0%) to 1.8% (sd = 0.2%)
depending on the chosen parameters set.
Conclusions: When the original PBC treatment plans were recalculated using AAA with the same number of
monitor units provided by PBC, the NTCPAAA was lower than the NTCPPBC, except for the breast treatments. The
NTCP is strongly affected by the wide-ranging values of radiobiological parameters.
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As a result of the increased sophistication of treatment
techniques and delivery methods, the accuracy of highly
conformal radiotherapy has improved rapidly with
technological advances in recent years. However more de-
manding modern treatment techniques require better
modeling of treatment beams and more sophisticated
modeling in the presence of inhomogeneities in order to
guarantee accuracy in the calculation of dose distribution.
In the clinical routine, calculations of dose to the tumor
are performed by commercial treatment planning systems
(TPS) and the majority of these systems include dose cal-
culation algorithms with a limited ability to account for
the effects of electron transport [1]. The Pencil Beam
Convolution (PBC) algorithm is commonly used in clinical
practice. However it is well known that it has shortcomings
regarding the presence of inhomogeneities, particularly in
those regions where charged particle equilibrium does not
exist [2-5]. The introduction of convolution-superposition
(CS) algorithms that better account for electron trans-
port, have enabled improved calculation of dose distribu-
tion, principally in the absence of electronic equilibrium
[6-11]. In the Eclipse TPS (Varian Medical Systems) the
Anisotropic Analytical Algorithm (AAA) is implemented;
it is a 3D pencil-beam kernel-based superposition algo-
rithm [12]. The AAA includes separately modeled contri-
butions from three sources: primary photons, extra-focal
photons and contaminating electrons; each of these has an
associated fluence, an energy deposition density function
and a scatter kernel. A better consideration of inhomo-
geneities is obtained when the AAA is used. The higher
accuracy of the AAA, compared to the Eclipse’s Pencil
Beam Convolution (PBC) algorithm is well-established
[13-16]. Monte Carlo (MC) simulation is considered to
be a gold standard in dose calculation, and it is there-
fore used to evaluate other dose calculation algorithms.
Sterpin et al. [17] investigated the accuracy of the AAA
in two studies. First the AAA was compared both with
MC and measurements in an inhomogeneous phantom.
Second, the AAA and MC were compared with four
Intensity Modulated Radiation Therapy (IMRT) treat-
ment plans in the presence of inhomogeneous tissue.
They showed good agreement between the AAA and
MC and evaluated the improved accuracy of the AAA
compared to the PBC algorithm.
Studies Fogliata et al. [18] carried out, show how
Collapsed Cone (CC) and AAA manifested a high degree
of consistency compared to the MC method, when the im-
pact of photon dose calculation algorithms on expected
dose distribution in lungs under different respiratory
phases was investigated. PBC proved to be severely defec-
tive in calculations, particularly for cases where specific
respiratory phases (e.g. deep inspiration breath hold) were
assumed for treatment.In the study of Bragg et al. [19] compared to the PBC
algorithm, the AAA was not found to significantly alter
the quality of IMRT treatments plans for prostate, parotid
or nasopharynx. While its more accurate modeling of
lateral electron transport demonstrates significant in-
creases in the volume of PTV being underdosed in IMRT
non-small cell lung cancer (NSCLC) treatments plans.
Nielsen et al. [20] investigated the differences in calcu-
lated dose distributions and NTCP values between six dif-
ferent dose calculation algorithms for NSCLC treatments.
The study showed how the calculated NTCP values for
pneumonitis were more sensitive to the choice of algo-
rithm than mean lung dose and V20 which are commonly
used for plan evaluation. Furthermore, NTCP for the
lungs was calculated using two different model parameter
sets; within each dose calculation algorithm, large dif-
ferences were found between the calculated NTCP values.
The aim of our study was the retrospective analysis of 3D
clinical treatment plans to investigate qualitative, possible
clinical consequences of the use of PBC versus AAA, which
was considered as benchmark data. The 3D dose distribu-
tions of 80 treatment plans at four different tumor sites,
produced using PBC algorithm, were recalculated using
AAA and the same number of monitor units provided by
PBC and clinically delivered to each patient. Similarly to
the study of Nielsen et al., in addition to the information re-
lating to the normal tissue/target dosimetry and the Tumor
Control Probability (TCP), the comparison was performed
investigating the consequences on the dose-effect rela-
tions for normal tissue injury comparing different Normal
Tissue Complication Probability (NTCP) model parame-
ters extracted from a review of published studies.
Several authors have proposed studies to compute
NTCP from a survey on clinical tolerance data [21,22].
After the first parameterization of dose-volume effects
reported by Burman et al. [23] and based on the expe-
rience from the 2D radiotherapy era, the availability of 3D
dose-volume information strongly increased the amount
of quantitative data. Consequently much effort was dedi-
cated both to the proposal of reliable dose-volume con-
straints that demonstrated capability to reduce toxicity,
and the development of normal tissue complication pro-
bability (NTCP) models properly fitting clinical data.
However NTCP models have been re-evaluated using 3D
dose data calculated by rather simple computation algo-
rithms; as it is difficult to quantify the clinical conse-
quence of approximate dose calculations, the value of
the reported NTCP parameters remains questionable.
De Jaeger et al. [24] compared the results of dose calcu-
lations in lung tissue using an approximate dose calcula-
tion algorithm (the equivalent-pathlength model, EPL)
with calculations for a convolution-superposition (CS)
algorithm, and the consequences with respect to the esti-
mation of normal lung tissue injury in a group of patients
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that when more accurate dose data is available, a re-
evaluation of NTCP model parameters is necessary to
avoid NTCP being grossly over or underestimated.
The degree to which the NTCP is strongly affected by
the wide-ranging values of radiobiological parameters is
shown in this study. At present, the evaluation of the
optimal values of the radiobiological parameters is diffi-
cult; absolute NTCP values are not reliable enough to be
considered for evaluating a treatment plan. However the
NTCP values have the attractive feature of synthesizing
in only one value the whole dose distribution through-
out the organ of interest and along with the dose-
volume parameters are useful tools for comparing rival
plans or for defining dose escalation strategies.
Methods
Patient data, treatment planning and delivery technique
3D clinical treatment plans of 80 patients were reviewed
for this study. 20/80 were irradiated for left breast cancer
with two tangential fields, 20/80 were treated for non-
small cell lung cancer (NSCLC) by three-dimensional
conformal radition therapy (3DCRT); as the PTV loca-
tions varied widely, the beam angles were adjusted for
each individual patient to meet both the set dose-volume
constraints for Organs At Risk (OAR) and acceptable dose
distributions. The tumor was situated in the middle or
lower lobe, eight plans required four fields; all others used
five fields. 20/80 patients were irradiated with intensity-
modulated radiotherapy for head-and-neck cancer using
seven coplanar fields arrangement [26]; finally 20/80
prostate cancer 3DCRT treatments plans (five coplanar
field technique 0°,45°,90°,270°,315°) were re-evaluated.
The target volumes were defined in accordance with the
1993 International Commission on Radiation Units and
Measurements Report 50 (ICRU Report 50). The gross
tumor volumes (GTV) included all known gross disease as
determined by imaging and clinical findings. GTVs were
expanded to yield corresponding clinical target volumes
(CTVs) according to clinical assessment in each case.
For breast cancer, the CTV was glandular breast tissue
and the PTV was generated by expanding the CTV by 0.7
cm isotropically, except in the direction of the skin sur-
face. For lung cancer, the stage was IIIA/IIIB (T3) with a
broad scope of disease; the GTV was similar to the CTV.
The radiation oncologist identified the GTV, and using a
margin of 0.3 cm, the CTV was delineated. A margin of
0.7 cm for middle lobe tumors and 1.0 cm for tumors in
the lower lobes was added to create the PTV. For head-
and-neck cancer, the margins were adjusted to 1.0 cm be-
yond the GTV to obtain the CTV; the CTV was expanded
symmetrically by 0.3 cm in all directions to account for
patient setup and motion within the thermoplastic mask.
For prostate cancer the CTV was considered to be theprostate plus seminal vesicles; the planning treatment
volume (PTV) was obtained by expanding in 3D the CTV
by 1.0 cm and 0.7 cm on the prostate–rectum interface to
avoid excessive rectal wall involvement.
All patients, except for five head-and- neck cases, were
treated with one fraction per day, 5 days a week, with the
fraction dose equal to 2Gy at the ICRU reference point
[27]. Five head-and-neck treatments receiving 69.96 Gy to
PTV1 and 59.40 Gy to PTV2 with simultaneous inte-
grated boost in 33 fractions, the remaining ones received
70.0 Gy, according to clinical risk. Respectively for lung,
prostate and breast cancer the prescription dose was 60.0,
76.0 and 50.0 Gy.
The treatment plans were developed using Eclipse 8.1
TPS (Treatment Planning System); the dose distributions
of the clinical treatment plans initially performed using
the PBC algorithm were recalculated with AAA using
the same number of monitor units provided by PBC.
The paired Student t-test was used for statistical com-
parison of all results obtained from the use of the two al-
gorithms. All tests were two-tailed with a p value of < 0.05
considered the threshold for statistical significance.
For the validation of both the algorithms implemented
in the TPS, the tests, the analyses, and the acceptability
criteria were in large part based on the report of the
AAPM Report 55 [28], and other documents such as the
technical report by IAEA [29] were consulted. For the
AAA, the outcomes of some tests were comparable to
those provided by Van Esch et al. [14].
Dose analysis
For the PTV we evaluated D95%, D2% dose levels on the
dose volume histogram (DVH) above which lay 95% and
2% of the volume of the PTV; they were used as a surro-
gate for dose minimum and dose maximum, respectively.
The mean dose to the PTV was also considered.
To describe the degree of the PTV dose inhomogeneity,
the Inhomogeneity Index (II) was used and it has been
calculated as (D2% −D95%)/Dmedian, II is equal to 0 if no
intra-target inhomogeneity is observed.
For breast treatments, D15%, D2% and the mean dose,
Dmean, to the heart and homolateral lung were assessed;
D2%, D20%, D60%, V20 (relative volume of the lung receiving
at least 20.0 Gy) and Dmean to the lung-CTV for NSCLC
treatments were considered; mean parotid glands dose for
head-and-neck treatment; finally D2%, D50%, D95% and
Dmean to the rectum and D2%, D50%, D80% to femoral heads
for prostate treatments were recorded.
NTCP and TCP analysis
The NTCP were evaluated by applying two different radio-
biological models: the Lyman-Kutcher-Burman (LKB)
model [21-23,30] and the relative seriality (RS) model
[31]. For the five head-and-neck simultaneous integrated
Table 2 Summary of NTCP modeling studies of lung toxicity
Organ: Lung; End-point: Pneumonitis
Ref. LKB model parameters Notes
n D50(Gy) m
Emami et al. [39] /
Burman et al. [23]†
0.87 24.50 0.18
Kwa et al. [60] 1.00 30.50 0.30
Seppenwoolde et al. [38] 0.99 30.80 0.37
De Jeager et al. [24]* 1.00 34.10 0.45
De Jeager et al. [24]** 1.00 29.20 0.45
Ref. Seriality model parameters Notes
γ D50(Gy) s
Emami et al. [39] /
Ågren-Cronqvist [40]‡
2.10 24.50 0.0061
Seppenwoolde et al. [38] 0.900 34.00 0.060
Gagliardi et al. [61] 0.966 30.10 0.012 lungs were
considered as
separate organs
†Clinical data from Emami et al. [39], model fitting by Burman et al. [23].
* Tissue inhomogeneity correction: Equivalent-path.
** Tissue inhomogeneity correction: Convolution-superposition.
‡Clinical data from Emami et al. [39], model fitting by Ågren-Cronqvist [40].
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2 Gy per fraction (EQD2) DVHs were calculated; α∕β = 3
Gy was assumed.
The NTCP and TCP calculation was performed by a
home-made software; the dose calculation in Eclipse was
calculated using the minimum available grid size, 0.25 cm,
and the step size for differential DVH export was chosen
to be 25 cGy, it was a compromise between time necessary
for TCP/NTCP calculation and the accuracy of the
computed values.
Six different combinations of NTCP model/parameters
were available for the heart, three quantifying the risk for
pericarditis, and three the excess risk for cardiac mortality.
For the lung we applied eight different model parameter
sets relating to the development of pneumonitis. The
lung-GTV is the volume considered from some of the
used NTCP parameter sets (e.g. De Jaeger et al. [24]) and
using these parameters on the lung-CTV volume would
generally be incorrect, as any differences in dose distribu-
tion from the PBC or AAA is most noticeable at the lung/
tumour interface. However because the tumor was at an
advanced stage and the GTV was similar to the CTV,
lung-GTV and lung-CTV were only slightly different.
Therefore using the NTCP model parameters for lung-
GTV on the lung-CTV may be suitable.
For quantifying the risk of xerostomia from irradiation
of the parotid glands we used three different combina-
tions of NTCP model/parameters. Seven sets of parame-
ters were used for the prediction of late rectal bleeding
in the patients treated for prostate cancer and only one
set of parameters relating to the necrosis of femoral
heads. The applied parameters are listed in Tables 1, 2,
3, 4, and 5.Table 1 Summary of NTCP modeling studies of cardiac
toxicity
Organ: Whole heart/ Pericard; End-point: Pericarditis
Ref. LKB model parameters Notes
n D50(Gy) m
Emami et al. [39] /
Burman et al. [23]†
0.35 48.00 0.10 whole heart
Martel et al. [57] 0.636 50.60 0.13 pericard (1cm
thick shell)
Ref. Seriality model parameters Notes
γ D50(Gy) s
Emami et al. [39] /
Ågren-Cronqvist [40] ‡
3 49.20 0.2 whole heart
Organ: Whole heart; End-point: Excess card.mortality
Gagliardi et al. [58] 1.28 52.40 1.00
Eriksson et al. [59] 0.93 63.30 1.00
Eriksson et al. [59] 0.96 70.30 1.00
†Clinical data from Emami et al. [39], model fitting by Burman et al. [23].
‡Clinical data from Emami et al. [39], model fitting by Ågren-Cronqvist [40].Using the LQ model the TCP was also calculated from
the DVH of the CTV. For head-and-neck, breast and
lung tumor α/β ratio of 10 Gy was used. At present
much debate is going on about the value of α/β for pros-
tate cancer. Modeling studies suggest that α/β could be
as low as 1.49 Gy, while other studies show higher α/β
[32-37]. Because valid data were not available, we de-
cided to do our investigation with two extreme values; a
α/β ratio of 1.49 Gy [32] and 10 Gy [37] were chosen,
subsequently, these sets of parameters are referred to as
α/β_1.49 and α/β_10 respectively.
Results
The results of the comparison of the treatment plans as cal-
culated by two algorithms, PBC and AAA, are summarized
in Tables 6, 7, 8, and 9 for breast, lung, head-and-neck and
prostate treatment respectively.
Subsequently, NTCP calculated with the AAA and PBC
algorithm are referred to as NTCPAAA and NTCPPBC, re-
spectively; the NTCP values less than 0.1% are assumed to
be zero.
The breast treatment
When AAA was used, the maximum percentage diffe-
rence was −3.3% for D95% and a increase of 2.0% for II was
found (Table 6). The poorer coverage of the PTV was
reflected in the TCP, which was significantly lower when
the AAA was used, the mean value was 77.3% (sd = 7.7%)
and 85.1% (sd = 4.3%) for PBC (p < 0.001). For the ipsila-
teral lung while mean D2% decreased when the AAA was
applied, the mean D15% and Dmean increased by 3.0 Gy
Table 5 NTCP modeling study of femoral heads toxicity
Organ: Femoral heads; End-point: Necrosis
Ref. LKB model parameters Notes
n D50(Gy) m
Emami et al. [39] / Burman et al. [23]† 0.25 65.00 0.12
†Clinical data from Emami et al. [39], model fitting by Burman et al. [23].
Table 3 Summary of NTCP modeling studies of parotid
glands toxicity
Organ: parotid glands; End-point: Total Xerostomia / 25% Xerostomia
Ref. LKB model parameters Notes
n D50(Gy) m
Emami et al. [39] /
Burman et al. [23] †
0.70 46.00 0.18 total xerostomia
Eisbruch et al. [41] 1.00 28.40 0.18 25% xerostomia
at 1 year
Roesink et al. [42] 1.00 39.00 0.45 25% xerostomia
at 1 year
†Clinical data from Emami et al. [39], model fitting by Burman et al. [23].
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higher than NTCPPBC (Figures 1 and 2). The mean
NTCPAAA varied from 0.2% (sd = 0.1%) to 2.1% (sd = 0.3%),
while the mean NTCPPBC varied from 0.1% (sd = 0.0%) to
1.8% (sd = 0.2%) depending on the chosen parameters set.
A mean increase of 0.1% was observed on the NTCPAAA
value when it was estimated by De Jeager et al. [24] para-
meters and re-evaluated using convolution-superposition
(CS) algorithm for the dose calculation. When the Seriality
Model was applied, the NTCP value estimated by
Seppenwoolde et al. [38] was lower than had been
predicted by the LKB model.
The incidence of radiation pneumonitis predicted by
both Emami et al. [39] / Burman et al. [23] and Emami
et al. [39] / Agren-Cronqvist [40] parameters was zero.
Following left breast cancer treatments, the risk of excess
cardiac mortality was found to be low; there was no statisti-
cally significant difference between the AAA and PBC. The
risk for developing pericarditis was zero for all the consid-
ered NTCP parameters. These results might be due to little
cardiac tissue having been exposed to radiation beam, but
on the other hand it is also necessary to consider that pres-
ently there are insufficient clinical data on the dose–Table 4 Summary of NTCP modeling studies of rectal
toxicity
Organ: Rectum; End-point: Late rectal bleeding
Ref. LKB model parameters Notes
n D50(Gy) m
Rancati et al. [62] 0.23 81.90 0.19 solid rectum including filling
Rancati et al. [62] 0.06 78.60 0.06 solid rectum including filling
Tucker et al. [45] 0.08 78.00 0.14 solid rectum including filling
Peeters et al. [63] 0.13 80.70 0.14 rectal wall
Söhn et al. [47] 0.08 78.40 0.11 rectal wall





Rancati et al. [62] 1.69 83.10 0.49 solid rectum including fillingresponse characteristics of cardiac tissue on which to base
reliable estimates of radiobiological parameters.
The lung treatment
Changes were observed specifically in the PTV coverage;
there was a mean percentage difference of about −3% for
the D95%, D2% and Dmean when the AAA was used and as a
result, a mean decrease of 8.3% for TCP was observed
(Table 7).
For the normal lung dose parameters, the AAA predicted
a mean reduction of 3.6 Gy for D2%, while the differences
for Dmean and D20% were not statistically significant. D60%
and V20% were found to be slightly higher when calculated
with the AAA than had been predicted by the PBC algo-
rithm. The resultant NTCPAAA values were lower than the
NTCPPBC (Figure 3). For both Seppenwoolde et al. [38]
and Emami et al. [39] / Burman et al. [23] parameters, the
comparison of NTCP values as calculated by two models,
LKB and RS, involved higher values if the LKB model was
applied.
When De Jaeger et al. [24] parameters were used we
found a mean increase of 4.3%: 14.9% (sd=7.2%) versus
10.6% (sd=4.8%), if the NTCPAAA was calculated with
the parameters evaluated from dose distribution based
on a CS algorithm.
The head-and-neck treatment
−3.7%, -2.9% and −3.4% were the percentage difference
between AAA and PBC for D95%, D2% and Dmean
respectively, and the differences were statistically signifi-
cant (Table 8). A reduction of 4% was observed in
the mean TCP with the use of the AAA.
The mean NTCPAAA of parotid gland toxicity values
were lower than NTCPPBC. Furthermore the NTCP
value obtained using Emami et al. [39]/Burman et al.
[23] parameters was lower than the value predicted by
the other sets of NTCP parameters. Using the Eisbruck
et al. [41] parameters, the risk of a decrease in the sal-
ivary flow to 25% of the pre-treatment flow at 1 year
post treatment was much higher (see Table 8) than the
risk calculated by Roesink et al. [42] parameters which
considered the same endpoint.
The prostate treatment
This type of treatment showed a markedly different
pattern. The present study showed no clinically significant
Table 6 Summary of differences between treatment plan and radiobiological parameters from the two algorithms for
breast treatment
Parameters AAA Mean sd PBC Mean sd p
PTV D2%(Gy) 51.5 0.7 52.2 0.7 <0.001
D95%(Gy) 47.1 0.8 48.7 0.6 <0.001
Dmean(Gy) 49.2 0.7 50.4 0.6 <0.001
II (%) 8.9 0.4 6.9 0.3 <0.001
TCP(%) 77.3 7.7 85.1 4.3 <0.001
Left Lung D2%(Gy) 44.1 1.3 48.0 1.6 <0.001
D15%(Gy) 7.0 1.5 4.0 1.2 <0.001
Dmean(Gy) 5.9 1.2 4.1 1.2 <0.001
LKB model
NTCP (%) Ref.
Emami et al. [39] / Burman et al. [23] 0.0 0.0 0.0 0.0
Kwa et al. [60] 0.2 0.1 0.1 0.0 <0.008
Seppenwoolde et al. [38] 0.7 0.1 0.6 0.1 <0.005
De Jeager et al. [24]† 2.0 0.3 1.6 0.2 <0.001
De Jeager et al. [24]†† 2.1 0.3 1.8 0.2 <0.001
Seriality model
Emami et al. [39]/ Ågren-Cronqvist et al. [40] 0.0 0.0 0.0 0.0
Seppenwoolde et al. [38] 0.2 0.1 0.1 0.1 <0.001
Gagliardi et al. [61] 0.2 0.1 0.1 0.1 0.020
Heart D2%(Gy) 37.7 12.5 37.5 13.3 0.758
D15%(Gy) 3.9 0.7 2.8 0.6 <0.001
LKB model
NTCP(%) Ref.
Emami et al. [39] /Burman et al. [23] 0.0 0.0 0.0 0.0
Martel et al. [57] 0.0 0.0 0.0 0.0
Seriality model
Emami et al. [39]/Ågren-Cronqvist et al. [40] 0.0 0.0 0.0 0.0
Gagliardi et al. [58] 0.6 0.4 0.6 0.4 0.243
Eriksson et al. [59] 0.6 0.3 0.6 0.3 0.482
Eriksson et al. [59] 0.4 0.2 0.4 0.2 0.418
† Tissue inhomogeneity correction: Equivalent-path.
†† Tissue inhomogeneity correction: Convolution-superposition.
Insignificant differences (p > 0.05) are in bold.
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(Table 9). The type of algorithm did not affect the II
(Figure 4). Across the two algorithms, the TCP was
within 2.0%. Regarding the rectum, the AAA predicted
slightly higher values for the dose parameters (though
statistically significant) except D2%. But on the other
hand when the PBC was used, low percentage of rectum
volume was exposed to a higher dose than had been
obtained with the AAA and the NTCPPBC was higher
than NTCPAAA (Figure 5).
The tissue-bone interfaces were encountered by the
lateral fields (90°, 270°); the slight shift towards higherdoses of the femoral heads DVH curve was found when
the AAA was used (Figure 5). Consequently, the only
available combination of parameters (Emami et al. [39] /
Burman et al. [23]) predicted a slightly higher risk of
necrosis, even if of limited clinical significance.
Discussion
Since the AAA is considered to be a more accurate
dose computation algorithm, the comparison between
the AAA and PBC dose distributions by the analyzed
dose indices, provides an indication of the difference
between the dose predicted by the PBC and that
Table 7 Summary of differences between treatment plan and radiobiological parameters from the two algorithms for
lung treatment
Parameters AAA Mean sd PBC Mean sd p
PTV D2%(Gy) 61.4 0.3 63.2 0.3 <0.001
D95%(Gy) 56.0 0.4 57.9 0.5 <0.001
Dmean(Gy) 58.7 0.4 60.5 0.3 <0.001
II(%) 11.0 0.6 9.0 0.6 <0.001
TCP(%) 78.4 3.0 86.7 1.0 <0.001
Lung D2%(Gy) 55.7 4.8 59.3 5.5 <0.001
D20%(Gy) 23.4 9.7 23.2 10.9 0.880
D60%(Gy) 4.1 3.0 3.0 2.5 <0.001
Dmean(Gy) 17.5 5.0 17.1 5.1 0.281
V20(%) 26.2 12.9 24.5 13.2 0.045
LKB model
NTCP (%) Ref.
Emami et al. [39] /Burman et al. [23] 28.5 16.3 33.0 16.3 0.040
Kwa et al. [60] 7.0 4.9 8.0 5.9 0.026
Seppenwoolde et al. [38] 8.9 5.4 9.8 6.1 <0.001
De Jeager et al. [24]† 10.6 4.8 11.4 5.2 0.024
De Jeager et al. [24]†† 14.9 7.2 15.6 7.0 0.055
Seriality model
Emami et al. [39] /Ågren-Cronqvist [40] 23.7 15.7 27.6 15.8 0.022
Seppenwoolde et al. [38] 7.9 4.7 8.8 5.4 <0.001
Gagliardi et al. [61] * 18.8 8.0 21.3 8.9 <0.001
Gagliardi et al. [61] ** 14.4 9.1 15.9 9.9 <0.001
* left lung; ** right lung.
† Tissue inhomogeneity correction: Equivalent-path.
†† Tissue inhomogeneity correction: Convolution-superposition.
Insignificant differences (p > 0.05) are in bold.
Table 8 Summary of differences between treatment plan and radiobiological parameters from the two algorithms for
head-and-neck treatment
Parameters AAA Mean sd PBC Mean sd p
PTV D2%(Gy) 64.4 4.6 66.3 4.9 <0.001
D95%(Gy) 60.2 4.6 62.5 5.0 <0.001
Dmean(Gy) 62.1 4.5 64.3 4.9 <0.001
II(%) 7.0 0.3 6.0 0.4 <0.001
TCP(%) 84.4 5.1 88.4 2.5 <0.001
parotid glands Dmean(Gy)
* 35.7 1.8 36.6 1.7 <0.001
Dmean(Gy)
** 34.0 4.7 34.9 4.3 0.02
Dmean(Gy) 35.0 4.0 36.2 3.9 <0.001
LKB model
NTCP (%) Ref.
Emami et al. [39] / Burman et al. [23] 12.8 3.0 15.2 2.7 0.002
Roesink et al. [42] 33.5 2.6 36.0 2.1 <0.001
Eisbruch et al. [41] 57.5 4.0 63.8 3.8 <0.001
* left parotid gland; ** right parotid gland.
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Table 9 Summary of differences between treatment plan and radiobiological parameters from the two algorithms for
prostate treatment
Parameters AAA Mean sd PBC Mean sd p
PTV D2%(Gy) 77.6 1.6 78.7 1.6 <0.001
D95%(Gy) 75.3 1.6 76.2 1.5 <0.001
Dmean(Gy) 76.5 1.5 77.4 1.6 <0.001
II(%) 3.2 0.1 3.2 0.2 0.416
TCP(%)α/β 1.49 81.9 5.1 83.9 4.3 <0.001
TCP(%)α/β 10.0 93.8 6.5 95.7 5.0 <0.001
Rectum D2%(Gy) 74.3 1.6 77.0 2.0 <0.001
D50%(Gy) 41.7 6.5 40.7 6.8 <0.001
D95%(Gy) 21.1 4.8 18.6 4.7 <0.001
Dmean(Gy) 44.6 6.2 43.9 6.6 0.002
LKB model
NTCP (%) Ref.
Rancati et al. [62] 3.3 1.9 3.9 2.5 0.005
Rancati et al. [62] 0.5 0.6 1.5 2.0 0.006
Tucker et al. [45] 9.2 2.2 11.5 2.3 <0.001
Peeters et al. [63] 3.1 1.9 4.1 2.9 <0.001
Söhn et al. [47] 4.5 1.8 6.4 2.6 <0.001
Rancati et al. [46] 9.1 2.2 11.1 2.2 <0.001
Seriality model
Rancati et al. [62] 3.0 1.8 3.5 2.4 0.013
Femoral heads D2%(Gy) 55.2 3.6 54.5 3.8 0.104
D50%(Gy) 44.6 6.9 43.6 7.3 <0.001
D80%(Gy) 26.1 5.7 25.1 6.0 <0.001
LKB model
NTCP(%) Ref.
Emami et al. [39] / Burman et al. [23] 0.2 0.1 0.1 0.1 <0.001
Insignificant differences (p > 0.05) are in bold.
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http://www.ro-journal.com/content/8/1/164actually delivered. In our study the consequences of
the difference on the dose-effect relations for normal
tissue injury were analyzed, comparing different NTCP
model/parameters.
The influence of the low density lung in proximity to
the target volume was the factor largely responsible for
the differences between the algorithms’ dose distribu-
tions for the breast plans. When AAA was used, the
increase of II was the result of the broadening of the
penumbra which was nicely modeled by the AAA; the
TCP was significantly lower.
Using a more accurate algorithm the radiation in the
lung was clearly transported further away; when the AAA
was used the mean D2% to the lung decreased by 8.1%.
This is in accordance with the findings by Knöös et al.
[16], which in their comparison of dose calculation
algorithms divided the algorithms in two groups based on
how changes in electron transport were accounted for; forthe breast plans, they found that the D5% to the adjacent
lung decreased by 9.5% or more when accurate algorithms
were used. While mean D2% decreased when the AAA
was applied, the mean D15% and Dmean increased; as result,
the mean NTCPAAA values were higher because the avai-
lable NTCP parameter sets described the lung by a preva-
lent parallel architecture for the analyzed endpoint. The
incidence of radiation pneumonitis predicted by both
Emami et al. [39] / Burman et al. [23] and Emami et al.
[39] / Agren-Cronqvist [40] parameters was zero. It is
worth remembering that the Emami et al. [39] study was
derived from the clinical experience of the 2D planning
era, without any individually assessed dose-volume infor-
mation; that most external radiation therapy was delivered
with opposing fields and the normal tissue was irradiated
with a fairly uniform dose fraction size.
It would be interesting to know the NTCP values for
the parameters estimated from Emami’s study. However
Figure 1 Comparison of NTCP for risk of developing pneumonitis following breast treatment computed with the AAA (ordinate)
and the PBC algorithm (abscissa) for NTCP models/parameters sets from Table 2. Each symbol represents data of an individual patient.
The dotted line indicates the line of identity.
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models to clinical and dosimetric data, have been pub-
lished and have to be considered to predict the risk of
normal tissue toxicity.
In the lung treatment, the extremely inhomogeneous
lung region resulted in the major difference of the two al-
gorithms’ abilities to account for inhomogeneities on the
final dose distribution. The factor responsible was the
widening of the penumbra, in fact looking closer at the
isodoses in proximity to the target revealed that they hadFigure 2 Example of a comparative DVH for a breast plan. The
curves calculated by the PBC algorithm are depicted by solid lines
and those calculated by the AAA by dotted lines.a larger separation when the more accurate AAA was ap-
plied and was worse for those treatments where a large
amount of lung tissue is involved in the PTV. These re-
sults are in agreement with the report of Bragg et al. [13],
who found that lung plans generated the most significant
issues in PTV coverage. When the AAA was used, a re-
duction for D2% was observed, while the differences for
Dmean and D20% were not statistically significant, contrary
to what was observed in the breast plans. The NTCPAAA
values were lower than the NTCPPBC. The highest NTCP
values and the maximum differences between NTCPAAA
and NTCPPBC were found for Emami et al. [39] parame-
ters. One can see from Table 2 how much these parameters
are markedly different than the other parameterizations,
whether for the LKB model or for the Seriality model.
The results obtained show how the use of NTCP
parameters based on more accurate dose calculation
should be recommended to avoid underestimating the
calculated values of NTCP. When De Jaeger et al. [24]
parameters were used the underestimate was not sig-
nificant when the lung tissue volume involved was
small, such as for breast treatments, but it was relevant
when the volume was major such as for lung treat-
ments; we found a mean increase of 4.3%, when the
NTCPAAA was calculated with the parameters evalu-
ated from dose distribution based on a CS algorithm.
In the head-and-neck treatments, as every beam passed
through a region of low density material the resulting dose
distributions of the two algorithms were dissimilar. A
Figure 3 Comparison of NTCP for risk of developing pneumonitis following NSCLC treatment computed with the AAA (ordinate) and
the PBC algorithm (abscissa) for NTCP models/parameters sets from Table 2. Each symbol represents data of an individual patient. The
dotted line indicates the line of identity.
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http://www.ro-journal.com/content/8/1/164reduction of the mean TCP and of the mean NTCP values,
quantifying parotid gland toxicity, was observed with the
use of the AAA.
Moreover using the Eisbruck et al. [41] parameters, the
NTCP value was much higher than the risk calculated by
Roesink et al. [42] parameters which considered the same
endpoint. This can be taken as a warning to radiation
oncologists: before introducing a predictive model into
clinical practice, it is necessary to assess if its predictionsFigure 4 Comparison of inhomogeneity index for treatment
plans computed with the AAA (ordinate) and the PBC
algorithm (abscissa) for the breast, NSCLC, head-and-neck and
prostate treatments. Each symbol represents data of an individual
patient. The dotted line indicates the line of identity.“make sense” in regard to that clinic’s treatment plans and
experience [43,44].
The dose distribution across the two algorithms was
found to be very similar in the prostate plans; no clini-
cally significant differences for any of the evaluated PTV
dose parameters were observed. Such small differences
between the dose distributions were found because only
two of the five beams used for these treatments were
such that there was involvement of heterogeneities.
When the PBC was used, a low percentage of rectum
volume was exposed to a higher dose than had beenFigure 5 Example of a comparative DVH for a prostate plan.
The curves calculated by the PBC algorithm are depicted by solid
lines and those calculated by the AAA by dotted lines.
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http://www.ro-journal.com/content/8/1/164obtained with the AAA and the NTCPPBC was higher
than NTCPAAA. That is consistent with a prevalent serial
architecture of the rectum for the analyzed endpoint.
The effect of the variability of the NTCP parameters on
the NTCP value is shown in Table 9. The major dif-
ferences between the two algorithms were for those set
of parameters with the n-parameter closer to 0; the
highest NTCP values were with the parameters proposed
by Tucker et al. [45] and Rancati et al. [46]. It is interes-
ting to note how a slight difference for the m-value and
D50-value between Tucker et al. [45] and Söhn et al. [47]
parameters resulted in an important difference in the
corresponding NTCP values.
The comparison of the two algorithms in the present
study is in accordance with the literature; the differences
are of minor clinical significance in many situations such
as for prostate treatments and probably for other lesions
in the pelvic area. The adoption of the AAA into clinical
treatment planning practice requires one to fully under-
stand its effect and its potential consequences so as to
re-evaluate an assessment of dose-effect relationships
and of parameters used in treatment planning decisions
[48]. Similarly the introduction of a predictive model
into clinical practice has to be prudent as it is necessary
to assess if it is based on calculations and treatments
similar to those for which the NTCP has to be calcu-
lated. The results found in this study show how the
NTCP is strongly affected by the wide-ranging values
of radiobiological parameters and the differences be-
tween the dose distributions of the two tested algo-
rithms yield statistically significant differences in the
NTCP values.
Conclusions
In this study, we have tried to investigate qualitative,
possible clinical consequences of the use of PBC versus
AAA (keeping the same number of monitor units pro-
vided by PBC and clinically delivered to each patient) by
comparing different NTCP model/parameters. As general
result, the NTCPAAA was lower than the NTCPPBC, except
for the breast treatments.
The difference in NTCP between PBC and AAA treat-
ment plans could be clinically significant and it may be
the subject of a future prospective study.
Moreover we have observed how much the NTCP
value depends strongly on the choice of radiobiological
parameters. Radiobiological modeling can play an import-
ant role in high quality radiotherapy, however uncritical
reliance on model results may compromise treatment out-
comes and patient safety. It is important to use NTCP par-
ameter sets based on calculations and treatments similar to
those for which the NTCP has to be calculated; addition-
ally, it is necessary to improve models and obtain more ro-
bust radiobiological parameters [49-56].Abbreviations
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